---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000029"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:54:54.281819+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Keros announces positive Phase 1 results for KER-065; plans Phase 2 in DMD in Q1 2026

## Summary
- KER-065 generally well-tolerated; no serious adverse events or dose-limiting toxicities reported.
- Evidence of activin inhibition: increases in BSAP, adiponectin, and bone density; decreases in CTX, leptin, and fat mass.
- Body composition changes included increased muscle mass and reduced fat mass consistent with activin inhibition.
- Company expects to initiate Phase 2 trial in Duchenne muscular dystrophy in Q1 2026 after regulatory engagement.
- Phase 1 data cut-off Feb 6, 2025; multiple ascending dose period through Day 85 completed.

## SEC filing metadata
- accession: 0001664710-25-000029
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000029/0001664710-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000029/kros-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000029
- JSON: https://secwatch.observer/filing/0001664710-25-000029.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.